首頁 > 市場調查報告書 > 醫療設備

藥物遞輸設備呼吸器

市場調查報告書

商品編碼

1410145

數位計量吸入器市場：2023年至2028年預測

Digital Dose Inhaler Market - Forecasts from 2023 to 2028

出版日期: 2023年12月13日 | 出版商:

Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計數位計量吸入器市場在預測期內將以 8.64% 的複合年成長率成長。

數位計量吸入器是一種緊湊的攜帶式設備，其中含有旨在緩解呼吸問題的藥物。透過向肺部輸送精確劑量的藥物，它可以有效治療氣喘、慢性阻塞性肺病（COPD）和其他呼吸困難等呼吸系統疾病。

慢性呼吸道疾病的增加將推動數位給藥市場的成長。

數位計量吸入器廣泛用於慢性呼吸道疾病的治療，因為它們能夠將精確劑量的藥物直接輸送到肺部，從而有效地控制症狀並改善治療結果。流感和呼吸道融合細胞病毒（RSV）等病毒感染疾病的增加，加上呼吸道疾病盛行率的上升以及污染問題，導致對數位計量吸入器的需求激增。根據美國疾病管制與預防美國的數據，2022 年 18 歲以上成年人中心絞痛的盛行率為 1.6%，而 2021 年為 1.5%。這顯示過去兩年成年人心絞痛的盛行率略有上升。

對研發活動的投資正在推動數位計量吸入器產業的發展。

製藥和醫療保健技術公司正在透過整合數位功能、智慧感測器和先進的連接來改善吸入器技術的研發投資。這些發展使得給藥更加準確、患者醫囑遵從性提高以及即時監測能力得以實現。此外，研究和開發工作正在促進個人化醫療解決方案的創建，根據患者的個別需求量身定做治療計劃並最佳化疾病管理。例如，瑞士製藥巨頭羅氏將研發支出從前一年的133億美元大幅增加至2022年的147億美元。這些策略投資正在推動數位計量吸入器市場的成長。

技術進步推動了數位計量吸入器市場的成長。

吸入器市場的尖端創新透過增強藥物輸送和監測能力，顯著提高了患者的準確性和易用性。智慧感測器透過提供吸入器使用情況的即時資料，使患者和醫療保健提供者能夠追蹤醫囑遵從性並調整治療計劃，從而推動了數位計量吸入器市場的需求。例如，藥物傳輸專家 Aptar Pharma 於 2022 年 2 月推出了 HeroTracker Sense。 HeroTracker Sense 是一種數位呼吸健康解決方案，可將標準計量吸入器 (pMDI) 轉變為智慧連線健診設備，從而能夠即時監控藥物使用情況，並提供有價值的資訊，以改善呼吸健康管理。

預計亞太地區將主導數位計量吸入器市場。

亞太地區將佔據重要的市場佔有率，因為氣喘發作的日益流行正在為採用數位計量吸入器創造有利的環境。例如，根據澳洲統計局的數據，2020 年至 2021 年間，約有 10.7% 的總人口（即 270 萬人）患有氣喘。政府提高醫療設備生產的措施也推動了市場成長。例如，印度政府於2023年4月核准的國家醫療設備政策旨在促進印度醫療設備產業的結構性擴張，並將該國打造為全球醫療設備製造領域的領導者。

隱私問題可能會限制數位計量吸入器市場的成長。

從患者和醫療機構的角度來看，將資料收集和傳輸功能整合到數位計量吸入器中引發了重大的隱私和安全問題。這些擔憂圍繞著敏感健康資料的潛在漏洞，這反過來可能會影響採用這些先進吸入器技術的意願和接受度。患者可能會猶豫是否使用此類設備，而不保證其個人健康資訊將受到保護，而醫療保健提供者和組織可能會猶豫是否要完全採用此類創新的吸入器解決方案。可能需要強力的資料保護措施。

A digital dose inhaler is a compact, portable device containing medicine designed to alleviate breathing issues. By delivering a precise dosage of medication into the lungs it effectively treats respiratory problems such as asthma, chronic obstructive pulmonary disease (COPD), and other breathing difficulties.

Growing chronic respiratory disease prevalence bolsters the digital dose market growth.

Digital dose inhalers are extensively used to treat chronic respiratory diseases due to their ability to deliver precise doses of medication directly into the lungs thereby effectively managing symptoms and improving treatment outcomes. The growing number of viral infections, such as influenza and respiratory syncytial virus (RSV) coupled with pollution problems are increasing the prevalence of respiratory conditions, thereby booming the digital dose inhalers demand. According to the Centers for Disease Control and Prevention, In the United States, the percentage of angina cases among adults aged 18 and over was 1.6% in 2022, compared to 1.5% in 2021. This indicates a slight increase in the prevalence of angina among the adult population between the two years.

Investments in R&D activities drive the digital dose inhaler industry.

Pharmaceutical companies and healthcare technology firms are improving their R&D investment in inhaler technology by incorporating digital features, smart sensors, and advanced connectivity. These developments result in more precise dosing, improved patient adherence, and real-time monitoring capabilities. Furthermore, R&D efforts are fostering the creation of personalized medicine solutions, tailoring treatment plans to individual patient needs, and optimizing disease management. For instance, Roche, the Swiss pharmaceutical giant, significantly increased its research and development (R&D) expenditure to $14.7 billion in 2022, marking a notable rise from the $13.3 billion spent in the previous year. Such strategic investments have propelled the digital dose inhaler market growth.

Technological advancements drive digital dose inhaler market growth.

The cutting-edge innovations in the inhaler market have significantly improved the precision and ease of use for patients by offering enhanced medication delivery and monitoring capabilities. The smart sensors provide real-time data on inhaler usage which enables patients and healthcare providers to track adherence and adjust treatment plans thereby promoting better disease management which has bolstered the digital dose inhaler market demand. For instance, in February 2022, Aptar Pharma, a specialist in drug delivery, services, introduced HeroTracker Sense, a digital respiratory health solution that transforms a standard metered dose inhaler (pMDI) into a smart connected healthcare device, enabling real-time monitoring of medication usage and providing valuable insights to improve respiratory health management

Asia-Pacific is expected to dominate the digital dose inhaler market.

Asia-Pacific will hold a significant market share due to the growing prevalence of asthma attacks thereby creating an environment conducive to digital dose inhaler adoption. For instance, according to the Australian Bureau of Statistics, from 2020 to 2021, approximately 10.7% of the total population, or 2.7 million individuals, were reported to have asthma. Also, supportive government initiatives to boost medical device production are additionally driving market growth. For instance, the National Medical Devices Policy, approved by the Indian government in April 2023, aims to foster a well-structured expansion of the medical device sector in India and to establish the country as a global leader in medical device manufacturing.

Privacy concerns may restrain the digital dose inhaler market growth.

The integration of data collection and transmission features in digital dose inhalers has brought forth significant concerns related to privacy and security, both from the perspective of patients and healthcare organizations. These anxieties revolve around the potential vulnerability of sensitive health data, and as a result, it may influence the level of willingness and acceptance in adopting these advanced inhaler technologies. Patients may be hesitant to use such devices without reassurance about safeguarding their personal health information, while healthcare providers and organizations may demand robust data protection measures before fully embracing these innovative inhaler solutions.

Key Developments

August 2022: Aptar Pharma, a leading provider of drug delivery and active material science solutions, completed the acquisition of Pharmaxis thereby acquiring global rights for the latter's "Orbital inhaler". The Orbital inhaler is an advanced device specifically developed for the delivery of high-payload dry powder directly to the lungs in clinical settings. This strategic move by Aptar Pharma strengthens its position in the field of drug delivery systems and expands its portfolio of innovative solutions for improving respiratory treatments.
December 2020: Berry Global, a leader in delivering innovative solutions for patient care in the healthcare market, achieved a significant milestone with its market-leading RS01 single-dose Dry Powder Inhaler (DPI) now equipped with built-in sensors and digital capabilities. As part of the newly-established Berry Global Healthcare, the advanced RS01X offers inhaler usage tracking and connects to a companion app, delivering personalized guidance to enhance patient adherence and improve inhaler technique.
May 2020: AstraZeneca formed a new partnership with Propeller Health to enhance its Symbicort inhaler by incorporating smart features. Propeller Health's connected platform will be integrated into AstraZeneca's Symbicort, enabling the digitization of asthma and chronic obstructive pulmonary disease (COPD) treatment. This collaboration revolutionized respiratory care, providing patients with valuable digital tools to monitor their inhaler usage and optimize their treatment plans.
January 2020: Aptar Pharma, renowned for its drug delivery systems and active packaging solutions, joined hands with Lupin Limited to introduce India's pioneering connected device for metered-dose inhalers (MDI) named ADHERO. This innovative add-on smart device serves as a breakthrough tool to support patients with chronic respiratory conditions, enabling them to monitor their MDI usage effectively and enhance adherence to prescribed therapies with advanced tracking capabilities, healthcare providers gain valuable insights to optimize treatment plans and achieve improved patient outcomes.

Segmentation

By Product

Metered Dose Inhaler (MDI)
Dry Powder Inhaler (DPI)

By Type

Branded Medication
Generic Medication

By Indication

Asthma
Chronic Obstructive Pulmonary Disease (COPD)
Others

By Geography

North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
Japan
China
India
South Korea
Indonesia
Thailand
Others

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Data
2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Force Analysis
- 4.3.1. Bargaining Power of Suppliers
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. DIGITAL DOSE INHALER MARKET, BY PRODUCT

5.1. Introduction
5.2. Metered Dose Inhaler (MDI)
5.3. Dry Powder Inhaler (DPI)

6. DIGITAL DOSE INHALER MARKET, BY TYPE

6.1. Introduction
6.2. Branded Medication
6.3. Generic Medication

7. DIGITAL DOSE INHALER MARKET, BY INDICATION

7.1. Introduction
7.2. Asthma
7.3. Chronic Obstructive Pulmonary Disease (COPD)
7.4. Others

8. DIGITAL DOSE INHALER MARKET, BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. United States
- 8.2.2. Canada
- 8.2.3. Mexico
8.3. South America
- 8.3.1. Brazil
- 8.3.2. Argentina
- 8.3.3. Others
8.4. Europe
- 8.4.1. United Kingdom
- 8.4.2. Germany
- 8.4.3. France
- 8.4.4. Spain
- 8.4.5. Others
8.5. The Middle East and Africa
- 8.5.1. Saudi Arabia
- 8.5.2. UAE
- 8.5.3. Israel
- 8.5.4. Others
8.6. Asia Pacific
- 8.6.1. Japan
- 8.6.2. China
- 8.6.3. India
- 8.6.4. South Korea
- 8.6.5. Indonesia
- 8.6.6. Thailand
- 8.6.7. Others